BeOne Medicines, a profitable biotech company, is expected to surpass an early buy point in the stock market this week. The company's key asset is Brukinsa, a successful drug that treats several blood cancers by targeting the BTK protein. This development has led Investor's Business Daily to feature BeOne as a top growth stock to watch. Investors are closely monitoring the stock as it could signal further gains based on Brukinsa's market performance.
BeOne Medicines is the subject of this update. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 01, 2026 23:41 WIB: Out of 100 priced health-sector US stocks, 22 rose and 78 fell. Notable movers include FLNA at USD 0.95 with a 7.56% increase and a typical hold time of 37 days, HRTX at USD 0.33 up 6.06% with a 35-day hold, and TMDX at USD 78.84 down 5.52% with a 24-day hold and 100% buy order activity.
Piper Sandler has set a $16 price target for V.F. Corp., suggesting a 12.2% upside from its current price of around $14.27. Analysts expect a slight decline in earnings per share to $0.51 and revenue to $2.70 billion, down 1.92% and 3.81% respectivel...
Raymond James increased its price target for e.l.f. Beauty from $100 to $117, reflecting the brand's significant retail expansion. e.l.f. Beauty's rhode brand is launching in over 500 Sephora stores across 19 new European markets, marking its first r...
Beneficient is set to report its Q3 2026 earnings on October 5, with analysts expecting $0.97 EPS and $13.1 million in revenue. The company is involved in disputes over allegedly fraudulent debt and equity claims linked to HCLP Nominees and former CE...
Robinhood Markets is broadening its platform with new features like AI-powered Robinhood Agents, crypto perpetual futures, earnings contracts, and social investing tools. The company plans to offer 24/7 trading for select U.S. stocks and ETFs, plus e...
Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Celsius Holdings securities between February 2025 and June 2026. The lawsuit alleges Celsius failed to disclose cardiac risks associated with its Alani Nu products, ...
